IFN-γ down-regulates the PD-1 expression and assist nivolumab in PD-1-blockade effect on CD8+ T-lymphocytes in pancreatic cancer

Combination therapy strategies for improving PD-1 blockade efficacy: a new era in cancer immunotherapy

(2017) P. S. Chowdhury et al.   JOURNAL OF INTERNAL MEDICINE

Prognostic value of programmed cell death protein 1 expression on CD8+ T lymphocytes in pancreatic cancer

(2017) Tao Shen et al.   Scientific Reports

Cancer statistics in China, 2015

(2016) Wanqing Chen et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Immunotherapy and tumor microenvironment

(2016) Haidong Tang et al.   CANCER LETTERS

Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients

(2016) Alena Gros et al.   NATURE MEDICINE

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

(2016) Jesse M. Zaretsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

(2016) Weiping Zou et al.   Science Translational Medicine

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adoptive cell transfer as personalized immunotherapy for human cancer

(2015) S. A. Rosenberg et al.   SCIENCE

Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice

(2014) Liufu Deng et al.   JOURNAL OF CLINICAL INVESTIGATION

In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates

(2014) C. Wang et al.   Cancer Immunology Research

Immune Modulation in Cancer with Antibodies

(2013) David B. Page et al.   Annual Review of Medicine

Recent progress in pancreatic cancer

(2013) Christopher L. Wolfgang et al.   CA-A CANCER JOURNAL FOR CLINICIANS

NK cell-based immunotherapy for malignant diseases

(2013) Min Cheng et al.   Cellular & Molecular Immunology

Improvement of surgical results for pancreatic cancer

(2013) Werner Hartwig et al.   LANCET ONCOLOGY

Innate and adaptive immune cells in the tumor microenvironment

(2013) Thomas F Gajewski et al.   NATURE IMMUNOLOGY

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel

(2011) J.- L. Van Laethem et al.   ANNALS OF ONCOLOGY

The role of the PD-1 pathway in autoimmunity and peripheral tolerance

(2011) Brian T. Fife et al.   Annals of the New York Academy of Sciences

Chimeric Antigen Receptors in Cancer Immuno-Gene Therapy: Current Status and Future Directions

(2011) Leonardo Chicaybam et al.   INTERNATIONAL REVIEWS OF IMMUNOLOGY

The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity

(2010) SaeGwang Park et al.   CANCER CELL

Cyclophosphamide Induces Differentiation of Th17 Cells in Cancer Patients

(2010) S. Viaud et al.   CANCER RESEARCH

The PD-1 pathway in tolerance and autoimmunity

(2010) Loise M. Francisco et al.   IMMUNOLOGICAL REVIEWS

A Systematic Review of Resectability and Survival After Concurrent Chemoradiation in Primarily Unresectable Pancreatic Cancer

(2009) Alessio G. Morganti et al.   ANNALS OF SURGICAL ONCOLOGY

Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNFα, and INFγ concentrations are elevated in patients with atypical and idiopathic parkinsonism

(2008) Bogdan Brodacki et al.   NEUROSCIENCE LETTERS